APOA5 and metabolic dysfunction-associated steatotic liver disease: Interestingly, higher apoA5 levels were observed in NAFLD group than controls, whereas metformin dose-dependently decreased apoA5 levels of these ob/ob mice, but these levels were not reduced to control levels.